NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nabla Bio

Nabla Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.nabla.bio/

Last Round

Series C

Jun 17, 2025

Total Funding Raised

$107.38M

Company Overview

Nabla Bio is a biotechnology company that develops an AI-driven platform for the rational design of developable, selective, and functional antibody therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Foundation

Keywords

protein designgenerative biologyAI drug discoveryde-novo protein designantibody engineeringcomputational biologyprotein language modelsbiotech AIdrug development platformtherapeutic designin silico drug discoverybiobucks

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nabla Bio Comparables

Compare Nabla Bio with similar companies based on industry and business-model similarity.

Nabla Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BigHat Biosciences
89%
Evozyne
85%
EvolutionaryScale
85%

Nabla Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 17, 2025
Series AMay 14, 2024
SeedDec 6, 2021
GrantApr 1, 2021
AcceleratorAug 24, 2020

Key People

Founding team and executive leadership

Surge Biswas

Co-founder CEO

Founding Team

Nabla Bio Investors

Notable investors and investment history

Nabla Bio investors
InvestorRounds
HV CapitalSeries C
DST GlobalSeries C
Khosla VenturesSeries A, Seed
Cantos VenturesSeed
Zetta Venture PartnersSeries A, Seed
Pillar VCSeries A, Seed
Y CombinatorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Received coverage in Science Magazine and Endpoints News.

  • Jan 1, 2026

    Partnerships disclosed with AstraZeneca, Takeda, and Bristol Myers Squibb.

Nabla Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nabla Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nabla Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range22
Year Founded2020
Last FundingJun 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.